(ECL) Ecolab - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US2788651006
Stock: Water Treatment, Sanitizers, Pesticides, Disinfectants, Filtration
Total Rating 57
Risk 87
Buy Signal -0.31
| Risk 5d forecast | |
|---|---|
| Volatility | 18.6% |
| Relative Tail Risk | -7.02% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.35 |
| Alpha | -1.83 |
| Character TTM | |
|---|---|
| Beta | 0.470 |
| Beta Downside | 0.409 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.26% |
| CAGR/Max DD | 1.24 |
EPS (Earnings per Share)
Revenue
Description: ECL Ecolab February 28, 2026
Ecolab Inc. (ECL) delivers water, hygiene, and infection-prevention solutions across four global segments-Water, Institutional & Specialty, Pest Elimination, and Life Sciences-serving industries from food processing to pharmaceuticals. Founded in 1923 and headquartered in Saint Paul, Minnesota, the company leverages brands such as Ecolab, Kay, Purolite, and Bioquell to sell through field sales teams, corporate accounts, distributors, and dealers.
In its most recent fiscal year (2025), Ecolab posted revenue of $4.3 billion, a 6 % year-over-year increase, driven by heightened demand for water-conservation technologies and stricter hygiene regulations worldwide. Operating margin expanded to 15.2 % and adjusted EPS rose to $5.20, while free cash flow topped $1.2 billion, underscoring strong cash generation amid a robust specialty-chemicals market.
Key macro drivers include escalating water scarcity, tightening environmental-health standards, and growth in the pharmaceutical and personal-care sectors-trends that bolster Ecolab’s recurring service contracts and premium-pricing power. For a deeper dive, you might explore ValueRay’s analyst notes on ECL.
Headlines to watch out for
- Industrial water treatment demand impacts Global Water segment revenue
- Food service and hospitality sector health drives Institutional sales
- Raw material and energy costs pressure profit margins
- Global health regulations increase demand for hygiene solutions
- Pest elimination services growth tied to commercial business activity
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 2.08b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.42 > 1.0 |
| NWC/Revenue: 2.62% < 20% (prev 9.35%; Δ -6.73% < -1%) |
| CFO/TA 0.12 > 3% & CFO 2.95b > Net Income 2.08b |
| Net Debt (8.78b) to EBITDA (3.49b): 2.52 < 3 |
| Current Ratio: 1.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (284.2m) vs 12m ago -0.53% < -2% |
| Gross Margin: 44.48% > 18% (prev 0.43%; Δ 4.40k% > 0.5%) |
| Asset Turnover: 68.34% > 50% (prev 70.38%; Δ -2.04% > 0%) |
| Interest Coverage Ratio: 9.82 > 6 (EBITDA TTM 3.49b / Interest Expense TTM 286.8m) |
Altman Z'' 3.41
| A: 0.02 (Total Current Assets 5.96b - Total Current Liabilities 5.53b) / Total Assets 24.70b |
| B: 0.52 (Retained Earnings 12.83b / Total Assets 24.70b) |
| C: 0.12 (EBIT TTM 2.82b / Avg Total Assets 23.53b) |
| D: 0.76 (Book Value of Equity 11.33b / Total Liabilities 14.89b) |
| Altman-Z'' Score: 3.41 = A |
Beneish M -2.99
| DSRI: 1.05 (Receivables 3.25b/3.02b, Revenue 16.08b/15.74b) |
| GMI: 0.98 (GM 44.48% / 43.47%) |
| AQI: 1.06 (AQ_t 0.55 / AQ_t-1 0.53) |
| SGI: 1.02 (Revenue 16.08b / 15.74b) |
| TATA: -0.04 (NI 2.08b - CFO 2.95b) / TA 24.70b) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of ECL shares?
As of March 18, 2026, the stock is trading at USD 272.59 with a total of 1,333,693 shares traded.
Over the past week, the price has changed by -2.87%, over one month by -10.03%, over three months by +4.36% and over the past year by +9.63%.
Over the past week, the price has changed by -2.87%, over one month by -10.03%, over three months by +4.36% and over the past year by +9.63%.
Is ECL a buy, sell or hold?
Ecolab has received a consensus analysts rating of 3.73.
Therefor, it is recommend to hold ECL.
- StrongBuy: 8
- Buy: 4
- Hold: 13
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the ECL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 321.9 | 18.1% |
| Analysts Target Price | 321.9 | 18.1% |
ECL Fundamental Data Overview March 16, 2026
P/E Trailing = 37.6104
P/E Forward = 32.1543
P/S = 4.8291
P/B = 7.9124
P/EG = 2.9187
Revenue TTM = 16.08b USD
EBIT TTM = 2.82b USD
EBITDA TTM = 3.49b USD
Long Term Debt = 7.37b USD (from longTermDebt, last quarter)
Short Term Debt = 870.4m USD (from shortTermDebt, last quarter)
Debt = 9.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.78b USD (from netDebt column, last quarter)
Enterprise Value = 86.44b USD (77.66b + Debt 9.43b - CCE 646.2m)
Interest Coverage Ratio = 9.82 (Ebit TTM 2.82b / Interest Expense TTM 286.8m)
EV/FCF = 45.39x (Enterprise Value 86.44b / FCF TTM 1.90b)
FCF Yield = 2.20% (FCF TTM 1.90b / Enterprise Value 86.44b)
FCF Margin = 11.84% (FCF TTM 1.90b / Revenue TTM 16.08b)
Net Margin = 12.91% (Net Income TTM 2.08b / Revenue TTM 16.08b)
Gross Margin = 44.48% ((Revenue TTM 16.08b - Cost of Revenue TTM 8.93b) / Revenue TTM)
Gross Margin QoQ = 44.03% (prev 44.79%)
Tobins Q-Ratio = 3.50 (Enterprise Value 86.44b / Total Assets 24.70b)
Interest Expense / Debt = 0.68% (Interest Expense 64.3m / Debt 9.43b)
Taxrate = 13.89% (91.7m / 660.3m)
NOPAT = 2.42b (EBIT 2.82b * (1 - 13.89%))
Current Ratio = 1.08 (Total Current Assets 5.96b / Total Current Liabilities 5.53b)
Debt / Equity = 0.97 (Debt 9.43b / totalStockholderEquity, last quarter 9.77b)
Debt / EBITDA = 2.52 (Net Debt 8.78b / EBITDA 3.49b)
Debt / FCF = 4.61 (Net Debt 8.78b / FCF TTM 1.90b)
Total Stockholder Equity = 9.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.82% (Net Income 2.08b / Total Assets 24.70b)
RoE = 22.03% (Net Income TTM 2.08b / Total Stockholder Equity 9.42b)
RoCE = 16.77% (EBIT 2.82b / Capital Employed (Equity 9.42b + L.T.Debt 7.37b))
RoIC = 13.89% (NOPAT 2.42b / Invested Capital 17.45b)
WACC = 6.89% (E(77.66b)/V(87.09b) * Re(7.65%) + D(9.43b)/V(87.09b) * Rd(0.68%) * (1-Tc(0.14)))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.51%
[DCF] Terminal Value 83.70% ; FCFF base≈1.87b ; Y1≈2.10b ; Y5≈2.81b
[DCF] Fair Price = 189.1 (EV 62.10b - Net Debt 8.78b = Equity 53.32b / Shares 282.0m; r=6.89% [WACC]; 5y FCF grow 14.34% → 2.90% )
EPS Correlation: 87.44 | EPS CAGR: 28.17% | SUE: 1.34 | # QB: 1
Revenue Correlation: 82.29 | Revenue CAGR: 6.90% | SUE: 0.85 | # QB: 2
EPS next Quarter (2026-06-30): EPS=2.14 | Chg7d=-0.013 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=18
EPS current Year (2026-12-31): EPS=8.49 | Chg7d=-0.024 | Chg30d=-0.042 | Revisions Net=+8 | Growth EPS=+12.8% | Growth Revenue=+8.3%
EPS next Year (2027-12-31): EPS=9.73 | Chg7d=-0.004 | Chg30d=-0.006 | Revisions Net=+5 | Growth EPS=+14.5% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: +0.00 (4 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.3% (Discount Rate 7.9% - Earnings Yield 2.7%)
[Growth] Growth Spread = +2.9% (Analyst 8.2% - Implied 5.3%)
P/E Forward = 32.1543
P/S = 4.8291
P/B = 7.9124
P/EG = 2.9187
Revenue TTM = 16.08b USD
EBIT TTM = 2.82b USD
EBITDA TTM = 3.49b USD
Long Term Debt = 7.37b USD (from longTermDebt, last quarter)
Short Term Debt = 870.4m USD (from shortTermDebt, last quarter)
Debt = 9.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.78b USD (from netDebt column, last quarter)
Enterprise Value = 86.44b USD (77.66b + Debt 9.43b - CCE 646.2m)
Interest Coverage Ratio = 9.82 (Ebit TTM 2.82b / Interest Expense TTM 286.8m)
EV/FCF = 45.39x (Enterprise Value 86.44b / FCF TTM 1.90b)
FCF Yield = 2.20% (FCF TTM 1.90b / Enterprise Value 86.44b)
FCF Margin = 11.84% (FCF TTM 1.90b / Revenue TTM 16.08b)
Net Margin = 12.91% (Net Income TTM 2.08b / Revenue TTM 16.08b)
Gross Margin = 44.48% ((Revenue TTM 16.08b - Cost of Revenue TTM 8.93b) / Revenue TTM)
Gross Margin QoQ = 44.03% (prev 44.79%)
Tobins Q-Ratio = 3.50 (Enterprise Value 86.44b / Total Assets 24.70b)
Interest Expense / Debt = 0.68% (Interest Expense 64.3m / Debt 9.43b)
Taxrate = 13.89% (91.7m / 660.3m)
NOPAT = 2.42b (EBIT 2.82b * (1 - 13.89%))
Current Ratio = 1.08 (Total Current Assets 5.96b / Total Current Liabilities 5.53b)
Debt / Equity = 0.97 (Debt 9.43b / totalStockholderEquity, last quarter 9.77b)
Debt / EBITDA = 2.52 (Net Debt 8.78b / EBITDA 3.49b)
Debt / FCF = 4.61 (Net Debt 8.78b / FCF TTM 1.90b)
Total Stockholder Equity = 9.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.82% (Net Income 2.08b / Total Assets 24.70b)
RoE = 22.03% (Net Income TTM 2.08b / Total Stockholder Equity 9.42b)
RoCE = 16.77% (EBIT 2.82b / Capital Employed (Equity 9.42b + L.T.Debt 7.37b))
RoIC = 13.89% (NOPAT 2.42b / Invested Capital 17.45b)
WACC = 6.89% (E(77.66b)/V(87.09b) * Re(7.65%) + D(9.43b)/V(87.09b) * Rd(0.68%) * (1-Tc(0.14)))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.51%
[DCF] Terminal Value 83.70% ; FCFF base≈1.87b ; Y1≈2.10b ; Y5≈2.81b
[DCF] Fair Price = 189.1 (EV 62.10b - Net Debt 8.78b = Equity 53.32b / Shares 282.0m; r=6.89% [WACC]; 5y FCF grow 14.34% → 2.90% )
EPS Correlation: 87.44 | EPS CAGR: 28.17% | SUE: 1.34 | # QB: 1
Revenue Correlation: 82.29 | Revenue CAGR: 6.90% | SUE: 0.85 | # QB: 2
EPS next Quarter (2026-06-30): EPS=2.14 | Chg7d=-0.013 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=18
EPS current Year (2026-12-31): EPS=8.49 | Chg7d=-0.024 | Chg30d=-0.042 | Revisions Net=+8 | Growth EPS=+12.8% | Growth Revenue=+8.3%
EPS next Year (2027-12-31): EPS=9.73 | Chg7d=-0.004 | Chg30d=-0.006 | Revisions Net=+5 | Growth EPS=+14.5% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: +0.00 (4 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.3% (Discount Rate 7.9% - Earnings Yield 2.7%)
[Growth] Growth Spread = +2.9% (Analyst 8.2% - Implied 5.3%)